Related Experiment Video
Updated: Jun 4, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[Advanced glycation end-products: new markers of renal dysfunction in patients with chronic heart failure]
Sergio Raposeiras-Roubín1, Bruno K Rodiño-Janeiro, Lilian Grigorian-Shamagian
1Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, España.
Insights
Advanced glycation end-products (AGE) are a reliable biomarker for detecting kidney disease (KD) in heart failure (HF) patients. AGE levels are higher in patients with kidney failure and better detect hidden kidney disease than cystatin C.
Area of Science:
- Cardiology
- Nephrology
- Biomarkers
Background:
- Advanced glycation end-products (AGE) are linked to heart failure (HF) pathophysiology and prognosis.
- AGE accumulation is observed in kidney failure (KF).
Purpose of the Study:
- To investigate the relationship between AGE and kidney failure in patients with chronic HF.
- To evaluate AGE as a potential biomarker for kidney disease in HF patients.
Main Methods:
- 102 chronic HF patients were analyzed.
- Clinical and analytical data were collected, including glycated hemoglobin, brain natriuretic peptide, cystatin C, and fluorescent AGE.
- Glomerular filtration rate (GFR) was estimated.
Main Results:
- 40.2% of patients had GFR < 60 mL/min/1.73 m²; 11.7% had hidden kidney disease (HKD).
- Fluorescent AGE positively correlated with creatinine and cystatin C, and negatively with GFR.
- Fluorescent AGE levels were significantly higher in patients with KF and showed superior diagnostic value for HKD compared to cystatin C.
Conclusions:
- AGE serve as a valuable biomarker for kidney disease in chronic HF patients, irrespective of diabetes status.
- Fluorescent AGE demonstrate superior efficacy over cystatin C in detecting hidden kidney disease in this population.
Background And Objectives:
Advanced glycation end-products (AGE) are implicated in the physiopathology and prognosis of heart failure (HF) and they accumulate in situations such as kidney failure (KF). Our objective was to analyze the relation between AGE and KF in patients with chronic HF.
Materials And Methods:
102 consecutive patients of our medical center were included. Clinical and analytical data were obtained, with measurement of glycated haemoglobin, brain natriuretic peptide, cystatin C and fluorescent AGE. Glomerular filtration rate (GFR) was estimated for each patient.
Results:
40.2% of patients presented GFR < 60 mL/min/1.73 m(2) and 11.7% had hidden kidney disease (HKD). AGE correlated positively with creatinine (r=0.685, p<0.001) and cystatin C (r=0.682, p<0.001) and negatively with GFR (r=-0.720, p<0.001). Medium value of fluorescent AGE in patients with KF was higher than those without KF (83.4 [3.3] URF vs 56.8 [2.1] URF, p<0.001). With regard to the diagnostic value for HKD, fluorescent AGE presented an area under the ROC curve higher than other parameters for KD such as cystatin C. In the multivariate analysis, fluorescent AGE were an independent biomarker of KD (OR 1.060; 95% CI 1.024-1.097; p=0.001).
Conclusions:
AGE act as a biomarker of KD in patients with chronic HF, both diabetics and non diabetics, being better than cystatin C in the detection of HKD.
Related Concept Videos
01:28Diabetic Nephropathy
01:29Heart Failure II: Pathophysiology
01:25Chronic Kidney Disease I: Introduction
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure III: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care